BioAge Labs, Inc.

Based in California, US, and founded in 2015 by co-founder Kristen Fortney and Eric Morgen, BioAge Labs, Inc. operates as a provider of an artificial intelligence-based platform that helps in discovering and developing drugs for age-related diseases. In February 2024, BioAge Labs, Inc. raised USD 194.

39 million in Series D funding led by Sofinnova Investments, with participation from Andreessen Horowitz. In September 2024, BioAge Labs, Inc. raised USD 198 million in an IPO, selling 11 million shares at USD 18 per share, within the expected USD 17-19 range, on the Nasdaq Global Select Market under the ticker symbol "BIOA. ".

BioAge Labs, Inc. has granted the underwriters a 30-day option to purchase up to an additional 1. 65 million shares of common stock as part of the listing. Following the transaction, Andreessen Horowitz retained a 6.

19% minority stake and Khosla Ventures retained a 5. 26% minority stake, respectively.   BioAge Labs, Inc. focuses on metabolic diseases and neuroinflammation by the molecular mechanisms of aging.

The company’s program, azelaprag (BGE-105), which is an oral therapeutic targeting obesity, acts as an APJ agonist, enhancing weight loss and improving body composition used in combination with incretin drugs. It’s program, BGE-100, which is an NLRP3 inhibitor treating metabolic diseases and neuroinflammation, addresses chronic inflammation by inhibiting the inflammasome component NLRP3, which is implicated in various age-related conditions. The company plans to use the funding from February 2024 to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline.